- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 7 - Ultimate Measures of Efficiency in Immuno-Oncology
People are now viewing cancer as a kind of chronic disease that can be held at bay, if it cannot be eliminated entirely, according to Kimberly Shafer-Weaver, PhD.
People are now viewing cancer as a kind of chronic disease that can be held at bay, if it cannot be eliminated entirely, according to Kimberly Shafer-Weaver, PhD.
“Right now we are looking at progression-free, stable disease as almost a win,” she said.
Keeping that in mind, Michael Kolodziej, MD, expects the rules will change, although he is skeptical that non-traditional endpoints will start to be implemented. The way those would be used, he said, would be to distinguish one of the many PD-1, PD-L1 drugs from the others.
“I think patient-reported outcomes are sorely lacking from the vast majority of work that has been done in oncology,” Dr Kolodziej said. “If we could find a way to collect that data and tie it to other more traditional endpoints that would be a great service.”
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More
